The purpose of this study was to demonstrate in adult patients a faster recovery from a neuromuscular block with 2.0 mg/kg Org 25969 (sugammadex) after rocuronium as compared to 50 ug/kg neostigmine after cisatracurium when administered at reappearance of T2

Inclusion Criteria:

• Subjects of ASA 1 - 4;
• Subjects above or equal to the age of 18;
• Scheduled for surgical procedures with a general anesthesia requiring neuromuscular relaxation with the use of rocuronium or cisatracurium;
• Scheduled for surgical procedures in supine position;
• Given written informed consent.

Exclusion Criteria:

• Subjects in whom a difficult intubation because of anatomical malformations was expected;
• Subjects known or suspected to have neuromuscular disorders impairing neuromuscular block (NMB) and/or significant renal dysfunction;
• Subjects known or suspected to have a (family) history of malignant hyperthermia;
• Subjects known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia;
• Subjects receiving medication in a dose and/or at a time point known to interfere with neuromuscular blocking agents such as antibiotics, anticonvulsants and Mg2+;
• Subjects in whom the use of neostigmine and/or glycopyrrolate may be contraindicated;
• Subjects who had already participated in an Org25969 trial;
• Subjects who had participated in another clinical trial (not pre-approved by NV Organon) within 30 days of entering into CT 19.4.310.
• Female subjects who are pregnant:
• Female subjects of childbearing potential not using any method of birth control: condom or using only hormonal contraception as birth control;
• Female subjects who were breast -feeding.